Repligen (RGEN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Repligen

NasdaqGS•Healthcare•Medical Instruments & Supplies

$176.93-1.78(-0.01%)Pre-market

Market Cap

$10.15B

P/S

12.6x

P/B

4.9x

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How this company scores

WeakMetricSide Score: 54/100

Grade capped at D — Interest coverage below 1× (0.8x) — earnings cannot cover interest. Strongest: Cash & Earnings Quality (18/25); weakest: Profitability (8/25).

Profitability8/25

Growth12/25

Balance Sheet & Red Flags16/25

Cash & Earnings Quality18/25

Strengths

Long cash runwayLow leverageCash-backed earningsConsistent free cash flow

Grade capped at D

Interest coverage below 1× (0.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 186.1x5y range 0.1x – 186.1x

Currently above its 14-quarter median.

P/S · 12.6x5y range 0.0x – 21.5x

Currently above its 20-quarter median.

P/B · 4.9x5y range 0.0x – 8.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Red Flag

Shares outstanding increased 100786.5% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $10.15B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $805.61M
Q. Revenue: $209.31M
TTM EBITDA: $136.23M
TTM Op. Income: $18.24M
Q. Op. Income: $-29.55M
TTM Net Income: $-11.80M
Q. Net Income: $-38.43M
EPS: $-0.68
Shares Out.: $56.56M

$805.61M in TTM revenue grew 12.8% YoY, reaching $209.31M last quarter. TTM EBITDA of $136.23M and TTM operating income of $18.24M show growth is flowing through to the bottom line. However, net income is negative at $11.80M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 53.0%
EBITDA Margin: -5.0%
Op. Margin: -14.1%
Net Margin: -18.4%

Op. margin of -14.1% is down 23.0% YoY — costs are rising relative to revenue. Net margin at -18.4% and gross margin of 53.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 12.6x
P/B Ratio: 4.9x

P/S of 12.6x and P/B of 4.9x. P/S is high, meaning growth expectations are priced in. Across the last 4 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.93B
Cash: $726.96M
Long-Term Debt: $555.60M
Book Value: $2.09B
D/E Ratio: 0.3
Debt/EBITDA: N/A

With $2.93B in assets and $555.60M in long-term debt, D/E is 0.3and book value is $2.09B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 3 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $43.10M
TTM Free Cash Flow: $106.72M
FCF Margin: 13.2%
FCF / Net Income: -9.0

TTM FCF of $106.72M on $43.10M in operating cash flow. The FCF / Net Income ratio of -9.0x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 3% — a weakening trend.